Sugi Predict

Sugi Predict / Compounds / SCHEMBL1015553

SCHEMBL1015553

SCHEMBL1015553

O=C(O)c1ccc(SC(F)(F)F)cc1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KCNK2 O95069 10/20 0.57
▸ KCNK10 P57789 8/20 0.57
▸ TSHR P16473 2/20 0.52
▸ TP53 P04637 1/20 0.52
▸ ALDH1A1 P00352 2/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ TRPV1 Q8NER1 1/20 0.50
▸ SRD5A2 P31213 2/20 0.48
▸ LMNA P02545 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ KIF11 P52732 1/20 0.47
▸ EPHX2 P34913 1/20 0.46
▸ NR1H4 Q96RI1 1/20 0.46
▸ PTPRZ1 P23471 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10407691 0.85 TSHR (0.50) KCNK2KCNK10TSHRTP53ALDH1A1
SCHEMBL27927082 0.85 ALDH1A1 (0.62) KCNK2KCNK10ALDH1A1EPHX2NR1H4
SCHEMBL10919991 0.84 LMNA (0.53) KCNK2KCNK10TSHRALDH1A1KDM4E
SCHEMBL10740573 0.83 ALDH1A1 (0.50) KCNK2KCNK10TSHRALDH1A1KDM4E
SCHEMBL282471 0.81 TRPV1 (0.49) KCNK2KCNK10TSHRALDH1A1KDM4E
SCHEMBL2541283 0.81 KIF11 (0.54) KCNK2KCNK10TSHRALDH1A1KDM4E
SCHEMBL1160810 0.81 HPGD (0.59) KCNK2KCNK10TSHRALDH1A1KDM4E
SCHEMBL735343 0.78 TSHR (0.52) TSHRTP53ALDH1A1TDP1SRD5A2
SCHEMBL9018876 0.78 TSHR (0.52) TSHRTP53ALDH1A1SRD5A2HTT
SCHEMBL11106674 0.78 KCNK2 (0.51) KCNK2KCNK10TSHRTP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119638770-A Clobetasol propionate derivative and preparation method thereof 复旦大学 2025-03-18 — — CN claimed
CN-119486565-A Perovskite precursor solution, perovskite solar cell, preparation method and photovoltaic module 天合光能股份有限公司 2025-02-18 — — CN claimed
CN-116836081-A Ether epoxy toughening agent and preparation method and application thereof 中国林业科学研究院林产化学工业研究所 2023-10-03 — — CN claimed
CN-113968804-A Hapten and artificial antigen of monel sulfone as well as preparation methods and application of hapten and artificial antigen 中国农业大学 2022-01-25 — — CN claimed
CN-108610912-A A kind of coating electronic device new material and preparation method thereof 天津安南科技有限公司 2018-10-02 — — CN claimed
CN-101250144-A Preparation method of 4-trifluoro-methylthio benzoic acid JINTAN LINGYUN CHEMICAL INDUST (CN) 2008-08-27 — — CN claimed
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives ORSOBIO, INC. (US) 2026-04-21 — — US disclosed
US-20260001886-A1 ENPP1 INHIBITORS I RE VENTURES I LLC (US) 2026-01-01 — — US disclosed
WO-2025233863-A1 ENPP1 INHIBITORS RE VENTURES I, LLC (US) 2025-11-13 — — WO disclosed
US-20250136570-A1 HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2025-05-01 — — US disclosed
CN-114206335-B KCNT1 inhibitors and methods of use 普拉克西斯精密药物股份有限公司 2025-03-11 — — CN disclosed
CN-119486565-A Perovskite precursor solution, perovskite solar cell, preparation method and photovoltaic module 天合光能股份有限公司 2025-02-18 — — CN disclosed
US-12209094-B2 CCR2 receptor antagonists and uses thereof CENTREXION THERAPEUTICS CORPORATION (US) 2025-01-28 — — US disclosed
US-6489338-B2 TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTION. BRISTOL-MYERS SQUIBB COMPANY 2002-12-03 — — US disclosed
EP-1212296-A1 PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS Sugen, Inc. (US) 2002-06-12 — — EP disclosed
US-20020016309-A1 Imidazopyridine and imidazopyrimidine antiviral agents BRISTOL-MEYERS SQUIBB COMPANY 2002-02-07 — — US disclosed
WO-2001095910-A1 IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2001-12-20 — — WO disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 — — EP disclosed
WO-2001016097-A1 PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS SUGEN, INC. (US) 2001-03-08 — — WO disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001886-A1 ENPP1 INHIBITORS I ENPP1, ENPP2, ENPP3 KCNK2 3533/4885KCNK10 2709/4885TSHR 1714/4885
US-20250136570-A1 HDAC INHIBITORS AND THERAPEUTIC USE THEREOF HDAC1, HDAC7, HDAC5 KCNK2 3704/4885KCNK10 4051/4885TSHR 4138/4885
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives NR3C2, NR5A1, SRD5A2 KCNK2 2235/4885KCNK10 2066/4885TSHR 83/4885
US-12209094-B2 CCR2 receptor antagonists and uses thereof CCR2, CCRL2, CCR1 KCNK2 1582/4885KCNK10 2754/4885TSHR 844/4885
US-20020016309-A1 Imidazopyridine and imidazopyrimidine antiviral agents MAVS, ZC3HAV1, EIF2AK2 KCNK2 3780/4885KCNK10 4275/4885TSHR 3281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.